Modus Therapeutics announces the appointment of Ellen K. Donnelly, Ph.D as Chief Executive Officer.
Dr. Donnelly joins Modus Therapeutics from Pfizer, Inc., where she has held numerous leadership positions in Clinical Operations; Project and Portfolio Management; and Research. Most recently she was responsible for Clinical Operations for Pfizer’s Neuroscience and Pain therapeutic area. Dr. Donnelly also brings biotech and consulting experience to the CEO role, having worked in positions within U.S. biotech and management consulting prior to her time at Pfizer. Dr. Donnelly received her Ph.D. from Yale University.
“I am thrilled to join Modus at this important time for the Company. SCD is a crippling disease affecting many hundreds of thousands of patients the world and Modus has a clear plan to address patients’ pain through both hospital and home-based treatment options. The high unmet medical needs of SCD patients require novel therapeutic options, and I look forward to working with patients and their families to ensure the best possible outcomes for this disease, as we further develop sevuparin for SCD,” commented Donnelly.
“We are pleased to welcome Dr. Donnelly as CEO and are confident her background and broad experience in global drug development will help drive Modus Therapeutics forward, as we continue patient recruitment in our Phase II clinical study with sevuparin for SCD,” sid Chairman of Modus Therapeutics, Björn Sjöstrand.
Dr. Donnelly will be based in Stockholm and will take up her appointment on 25 April 2017. She succeeds Dr. Christina Herder.